Fenoldopam in critically ill patients with early renal dysfunction. A crossover study

Miguel Cobas, Gian Paparcuri, Maria de la Pena, Gaston Cudemus, Erik Barquist, Albert Varon

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an option to prevent further damage. Methods: We performed a randomized, double-blinded, prospective crossover study in 17 patients admitted to our trauma intensive care unit (ICU) with evidence of impaired renal function. Patients were randomized to a 24-h intravenous infusion of low-dose fenoldopam or placebo. When the infusion of fenoldopam or placebo was completed, patients underwent a 24-h "washout" period in which no study intervention was performed. This sequence was repeated in each patient with the opposite agent, so each patient served as his own control. Four-hour creatinine collections were taken during the last 4 h of each infusion and washout periods to determine creatinine clearance changes during and after the administration of the study drug. Results: The creatinine clearance was higher with fenoldopam infusion than with placebo infusion (P= 0.045). The FENa was not significantly different. Conclusions: Our study showed that low-dose Fenoldopam increases creatinine clearance in the critically ill with renal insufficiency. Fenoldopam may be a useful drug in ICU patients with early renal dysfunction.

Original languageEnglish (US)
Pages (from-to)280-284
Number of pages5
JournalCardiovascular Therapeutics
Issue number4
StatePublished - Aug 2011


  • Critical care
  • Medicine
  • Pharmacology
  • Renal dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Fenoldopam in critically ill patients with early renal dysfunction. A crossover study'. Together they form a unique fingerprint.

Cite this